Harold Bays

Louisville Metabolic and Atherosclerosis Research Center Inc (L-MARC), United States of America

Harold Bays MD, FACP
Medical Director President
L-MARC Research Center
3288 Illinois Avenue
Louisville KY 40213
www.lmarc.com

Harold Bays, MD, FACP is Medical Director and President of Louisville Metabolic and Atherosclerosis Research Center (L-MARC) and continues to see oversee patient care for Louisville Endocrinology P.S.C., - a private medical practice in Louisville, Kentucky. Dr. Bays received his medical degree, completed his Internship and Residency in Internal Medicine, and received his Fellowship in Endocrinology and Metabolism all at the University of Louisville School of Medicine. He is board certified in both Internal Medicine and Endocrinology and Metabolism.

 Dr. Bays has served as a Principal Investigator for over 300 clinical trials, including studies of all currently marketed lipid-altering drug treatments, as well as studies of investigational drugs for obesity, diabetes mellitus, hypertension, osteoporosis, osteoarthritis, and other metabolic disorders. He has written, or has been a contributing author to over 100 published peer-reviewed scientific manuscripts, abstracts, and medical/scientific book chapters. Specifically, he has been a published author in journals such as: Obesity Research, Journal of Clinical Endocrinology and Metabolism, Medical Clinics of North America, Metabolism, Drug Development & Research, Circulation, Atherosclerosis, Expert Opinion on Investigational Drugs, Journal of Cardiovascular Therapy, Expert Opinion on Pharmacotherapy, Progress in Drug Research, Journal of Clinical Pharmacology, American Journal of Cardiology, Drug Safety, Clinical Therapeutics, Journal of Clinical Investigations in Arteriosclerosis, American Journal of Kidney Disease, American Journal of Cardiovascular Drugs, Preventive Cardiology, Expert Review of Cardiovascular Therapy, Evidence-based Cardiovascular Medicine, European Heart Journal, Clinical Cardiology, Future Cardiology, International Journal of Clinical Practice, Coronary Artery Disease, European Journal of Neurology, Hospital Pharmacy Europe, Nature Clinical Practice Cardiovascular Medicine, Nutrition Metabolism & Cardiovascular Disease, Journal of Women’s Health, and has been a scientific contributor to www.lipidsonline.org.

Dr. Bays originated the term "adiposopathy", which is defined as pathogenic adipose tissue which is promoted by positive caloric balance and sedentary lifestyle in genetically and environmentally susceptible patients, which may be anatomically manifested by adipocyte hypertrophy, visceral adipose tissue accumulation, and ectopic fat deposition, and physiologically results in adverse metabolic and immune consequences resulting in clinical metabolic disease. He has published several manuscripts on the adipocentric paradigm wherein pathogenic adipose tissue represents a rational, unifying cause of excessive fat-related metabolic diseases. Dr. Bays is Chairman of the American Association of Clinical Endocrinologists (AACE) Task Force on Pathogenic Adipose Tissue. Dr. Bays is also Chairman of the study group overseeing the "Study to Help Improve Early evaluation and management of risk factors Leading to Diabetes" (SHIELD), which is the the largest survey of its kind, designed as a cross-sectional and subsequent longitudinal study of various parameters relevant to metabolic diseases, including diabetes mellitus.

He has served as an expert manuscript reviewer for scientific medical journals including: Journal of the American Medical Association (JAMA), The Lancet, Archives of Internal Medicine, Obesity Research/Obesity, Journal of the American College of Cardiology (JACC), Methods and Findings in Experimental and Clinical Pharmacology, Opinion in Molecular Therapeutics, Annuals of Nutrition and Metabolism, Biochemical Pharmacology, Vascular Health and Risk Management, Drug Discovery Today, Investigational Drug Database, Trends in Pharmacological Sciences, Expert Opinion on Biologic Therapy, Drugs, Journal of the American College of Nutrition, American Journal of Cardiovascular Drugs, Expert Opinion on Pharmacotherapy, Expert Opinion on Investigational Drugs, International Journal of Clinical Practice, Pharmacological Research, Expert Opinion on Drug Safety, Consultant, Future Lipidology, Nature Clinical Practice Cardiovascular Medicine, Expert Opinion on Therapeutic Targets, Treatments in Endocrinology, Journal of Clinical Outcomes Management, Vascular Health and Risk Management, and Journal of Cardiovascular Drugs. Dr. Bays has presented poster abstracts and/or given oral presentations of abstracts regarding cardiovascular disease, obesity, and diabetes mellitus at various scientific meetings, international symposia, and university conferences.

Finally, Dr. Bays serves as a national and international advisor and consultant for pharmaceutical companies in protocol and drug project development, and has given hundreds of invited educational presentations, including Continuing Educational Education (CME) programs.

Dr. Bays is a Fellow of the North American Association for the Study of Obesity (NAASO) and a Fellow of the American College of Physicians (FACP). He is a member of the American Diabetes Association (ADA) - and has been a “Recognized” provider in the ADA’s NCQA Diabetes Physician Recognition Program since 1998. Dr. Bays is also a member of the American Association of Clinical Endocrinologists (AACE), the American Society of Bariatric Physicians (ASBP), the American Medical Association (AMA), the Kentucky Medical Association (KMA) and has been honored with academic awards, as well as for his longstanding physician volunteer work for the homeless.

Any competing interests declared are displayed with individual evaluations.

Faculty Member: Diabetes & Endocrinology > Diabetes & Obesity (since 02 April 2007)

Links

http://www.lmarc.com

All recent recommendations

• 6.0
  Differences in basal energy expenditure and obesity.
  Recommended by Harold Bays
  
• 3.0
  Larger anti-adipogenic effect of angiotensin II on omental preadipose cells of obese humans.
  Recommended by Harold Bays
  
• 6.0
  Waist Circumference and Cardiometabolic Risk: a Consensus Statement from Shaping America's Health: Association for Weight Management and Obesity Prevention; NAASO, the Obesity Society; the American Society for Nutrition; and the American Diabetes Association.
  Recommended by Harold Bays
  
• 6.0
  Glucose metabolism and the response to insulin by human adipose tissue in spontaneous and experimental obesity. Effects of dietary composition and adipose cell size.
  Recommended by Harold Bays